BridgeBio Oncology Therapeutics, Inc. (BBOT)
| Market Cap | 716.76M -15.0% |
| Revenue (ttm) | n/a |
| Net Income | -182.11M |
| EPS | -5.84 |
| Shares Out | 80.17M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 398,957 |
| Open | 9.02 |
| Previous Close | 9.04 |
| Day's Range | 8.82 - 9.13 |
| 52-Week Range | 7.00 - 14.87 |
| Beta | 0.36 |
| Analysts | Strong Buy |
| Price Target | 24.90 (+178.52%) |
| Earnings Date | Aug 11, 2026 |
About BBOT
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for BBOT stock is "Strong Buy." The 12-month stock price target is $24.9, which is an increase of 178.52% from the latest price.
News
BridgeBio Oncology price target lowered to $25 from $27 at JPMorgan
JPMorgan analyst Priyanka Grover lowered the firm’s price target on BridgeBio Oncology (BBOT) to $25 from $27 and keeps an Overweight rating on the shares. The firm updated the company’s…
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignan...
BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
Continued to advance monotherapy and combination cohorts for all clinical programs Initiated dosing of BBO-11818 in combination with cetuximab and after the end of the quarter, initiated dosing of BBO...
BridgeBio Oncology Therapeutics Earnings release: Q2 2026
BridgeBio Oncology Therapeutics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
BridgeBio Oncology Therapeutics Quarterly report: Q2 2026
BridgeBio Oncology Therapeutics has published its Q2 2026 quarterly earnings report on August 11, 2026.
BridgeBio Oncology initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of BridgeBio Oncology (BBOT) with an Overweight rating and $27 price target Initial phase 1 data readouts from the BBO-8520, BBO-11818, and BBO-10203 programs provide “earl...
BridgeBio Oncology assumed with an Outperform at Oppenheimer
Oppenheimer assumed coverage of BridgeBio Oncology (BBOT) with an Outperform rating and $22 price target The oncology pipeline is viewed as differentiated across multiple RAS-targeted programs, led by...
BridgeBio Oncology Therapeutics Transcript: AGM 2026
Shareholders approved the election of two directors and ratified Deloitte & Touche as auditor for 2026. No questions were raised, and all proposals passed with the required majority. Final results will be reported in meeting minutes and SEC filings.
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignanc...
BridgeBio Oncology Therapeutics Earnings release: Q1 2026
BridgeBio Oncology Therapeutics released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
BridgeBio Oncology Therapeutics Quarterly report: Q1 2026
BridgeBio Oncology Therapeutics has published its Q1 2026 quarterly earnings report on May 12, 2026.
BridgeBio Oncology initiated with a Buy at Canaccord
Canaccord initiated coverage of BridgeBio Oncology (BBOT) with a Buy rating and $23 price target The company is developing RAS inhibitors positioned for effective and tolerable combinations, the analy...
BridgeBio Oncology initiated with a Buy at Canaccord
Canaccord analyst John Newman initiated coverage of BridgeBio Oncology (BBOT) with a Buy rating and $23 price target
BridgeBio Oncology Therapeutics Proxy statement: Proxy filing
BridgeBio Oncology Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
BridgeBio Oncology Therapeutics Proxy statement: Proxy filing
BridgeBio Oncology Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026
BBO-11818 targets KRAS in both its ON (active GTP-bound) and OFF (inactive GDP-bound) states, potently suppressing MAPK signaling and inhibiting cell proliferation in KRAS-mutant cell lines
BridgeBio Oncology appoints Pedro Beltran as CEO, Idan Elmelech as COO
BridgeBio Oncology (BBOT) announced the appointment of Pedro Beltran as CEO and Idan Elmelech as COO effective April 20. This transition reflects BridgeBio Oncology entering a new phase of development...
BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman
Pedro J. Beltran, PhD, a seasoned executive who previously served as Chief Scientific Officer of BBOT, will assume the position of Chief Executive Officer, bringing his extensive drug development exp...
BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026
BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to signaling inhibition without inhibiting the kinase activity of PI3Kα and with no observed hyperglycem...
BridgeBio Oncology announces FDA Fast Track Designation for BBO-11818
BridgeBio Oncology (BBOT) Therapeutics announced that the FDA has granted Fast Track designation to BBO-11818 for the treatment of adult patients with advanced KRAS-mutant pancreatic ductal adenocarci...
BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma
BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors
BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway maligna...
BridgeBio Oncology Therapeutics Transcript: Leerink Global Healthcare Conference 2026
The company is advancing three differentiated oncology programs targeting RAS and PI3K pathways, with all major clinical readouts expected in the second half of 2026. Early data show strong efficacy and safety, especially for the G12C and pan-KRAS inhibitors, and multiple combination trials are underway.
BridgeBio Oncology announces publication of preclinical data on BBO-11818
BridgeBio Oncology (BBOT) Therapeutics announced the publication of preclinical data describing the discovery and characterization of BBO-11818, a panKRAS inhibitor targeting KRAS in both the ON and O...
BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor
BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over HRAS and NRAS, and displays strong activity in KRAS muta...